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Abstract. We formulate an individual-based model and an integro-diﬀerential model
of phenotypic evolution, under cytotoxic drugs, in a cancer cell population structured
by the expression levels of survival-potential and proliferation-potential. We apply these
models to a recently studied experimental system. Our results suggest that mechanisms
based on fundamental laws of biology can reversibly push an actively-proliferating, and
drug-sensitive, cell population to transition into a weakly-proliferative and drug-tolerant
state, which will eventually facilitate the emergence of more potent, proliferating and
drug-tolerant cells.
1 Introduction
In recent experiments, performed on genetically homogeneous populations of cancer cells, Sharma
and co-workers [1] showed that epigenetically regulated changes in phenotype can play an important
role in the development of reversible drug tolerance. During these experiments, a small subpopula-
tion of drug-tolerant cells was consistently detected, that could maintain viability in the presence of
high-dose drug therapy. These Drug-Tolerant Persisters (DTPs) were shown to be non-proliferative
and display markers speciﬁc to stem cell-like cancer cells. After a period of time, approximately 20
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percent of DTPs changed their phenotype to resume normal proliferation and lost stem-like mark-
ers, still in the constant presence of the drugs. The resulting cells were labeled the Drug-Tolerant
Expanded Persisters (DTEPs). Interestingly, both DTPs and DTEPs could be drug resensitized by
drug-free passaging.
Therefore, the three distinct subpopulations— the parental cancer cells (PC9s), DTPs and
DTEPs—that compose the whole cancer cell population at various times during drug treatment,
although genetically identical, possess diﬀerent functional phenotypes. Most notably, they can be
characterized by their respective levels of survival potential (i.e., the level of robustness towards life-
threatening events in extreme conditions, which in this case can be identiﬁed as the level of drug
tolerance) and proliferation potential (i.e., the rate of cell proliferation) [2]. But what is driving the
evolution of phenotypes observed in the PC9 cancer cells? Is it simply a case of selection, where cells
with certain properties survive and proliferate better in a given environment [3]? Are individual cells
changing their properties in response to environmental cues [4, 5]?
In order to address these questions, in [6] we proposed an Individual-Based (I-B) computational
model [4, 7–9] and an Integro-Diﬀerential Equation (IDE) model [10–12] of the phenotype evolution
observed in [1]. Such models can be used as in silico laboratories to test verbal hypotheses, and un-
cover mechanisms that underlie emergent features of cancer cell populations. The I-B computational
model allows an intuitive and ﬂexible description of the system at hand, while the IDE model makes
it possible to study the system in terms of qualitative and asymptotic analysis, and is computationally
less expensive.
2 Model
We describe the evolution of phenotype in a well-mixed PC9 cancer cell population exposed to cyto-
toxic drugs using both an I-B and an IDE formalism. The concentration of cytotoxic drugs at time t is
modeled by the function c(t), and we characterize the state of each PC9 cell by its expression levels of
two phenotypic traits: survival potential and proliferation potential. In this framework, we identify a
PC9 cell as having a low value of survival potential and a high value of proliferation potential, a DTP
cell as having a high value of survival potential and a low value of proliferation potential, and a DTEP
cell as having a high value of survival and proliferation potential.
We model the key biological mechanisms of phenotype evolution in the PC9 cancer cells, namely
selection, stress-induced adaptation and non-genetic phenotype instability, by using three separate
mathematical strategies, which are tailored to ﬁt the I-B and the IDE formalisms. Selection is mod-
eled through a proliferation probability p and a death probability d, which depend on the levels of
proliferative and survival potentials of the cells, as well as on the cell micro-environment at time t.
Importantly, since DTPs and DTEPs exhibit vastly diﬀerent proliferation rates, we assume that d does
not vary with proliferation potential. On the other hand, we assume that maintaining a high survival
potential in a drug-free environment is costly to a cell and will act to reduce p [2, 13, 14]. Finally,
we assume that p is dependent on the total population size, to represent competition between cells for
space and nutrients. This dependence could also be introduced in d without altering the qualitative
results of the model.
Stress-induced adaptation of cell proliferation level is modeled by an advection term that leads to a
decrease in the level of proliferation. The speed of adaptation v depends on the cell micro-environment
at time t, the level of survival potential and the average sensitivity of the cell proliferative potential to
stress-inducing agents v¯.
Finally, we assume that small (large) epimutations correspond to small (large) changes in cell
properties, and also that small epimutations occur at a much higher frequency than large epimuta-
tions [15]. Therefore, non-genetic phenotype instability is modeled as Brownian motion, or diﬀusion,
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in the levels of cell proliferation and survival potentials.
Individual-based model
In the I-B formalism, we consider each cell as an individual agent, and label it by an index
0 ≤ i ≤ N(t), where N(t) ≥ 0 is the size of the population at time t ∈ [0,T ], and T is the
end time of in silico experiments. The normalized expression levels of the survival-potential and
proliferation-potential traits, in each cell i at time t, are modeled, respectively, by the random vari-
ables Xi(t) : [0,∞)→ [0, 1] and Yi(t) : [0,∞)→ [0, 1].
If a cell proliferates, we assume both daughter cells inherit the parent’s trait values. After all cells
have undergone one iteration of the proliferation and death process, and returned to the quiescent
state, we then let each cell update its trait values according to the following system of discretized
Stochastic Diﬀerential Equations:
Xi(t + Δt) = Xi(t) + D
√
Δt W1i (t),︸︷︷︸
non-genetic
instability
Yi(t + Δt) = Yi(t) + D
√
Δt W2i (t)︸︷︷︸
non-genetic
instability
+ Δt v(Xi(t), c(t); v¯),︸︷︷︸
stress-induced adaptation
of the proliferation level
(1)
where W1i (t) and W
2
i (t) are standard normal random variables for all 0 ≤ i ≤ N(t) and t ≥ 0, and D is
the average rate of phenotypic ﬂuctuations.
Integro-differential equation model
In the IDE formalism, we consider the cell population to be structured by two continuous, real
variables x ∈ [0, 1] and y ∈ [0, 1], which represent, respectively, the normalized expression levels of
survival potential and proliferation potential. The population density of cancer cells is modeled by
the function n(x, y, t) ≥ 0, where the global population density at time t ∈ [0,T ] is computed as
(t) =
∫ 1
0
∫ 1
0
n(x, y, t) dxdy,
and the evolution of n is governed by the following equation:
∂n
∂t
(x, y, t) +
∂
∂y
(
v(x, c(t); v¯)n(x, y, t)
)
︸︷︷︸
stress-induced adaptation
of the proliferation level
=
[
p(x, y, (t)) − d(x, c(t))
]
n(x, y, t)︸︷︷︸
selection
+
D2
2
Δn(x, y, t)︸︷︷︸
non-genetic
instability
. (2)
3 Main Results
In [6], we showed that these models are capable of reproducing the main experimental observations
detailed in [1]. Our analysis highlighted the important role of non-genetic ﬂuctuations in phenotype
in the emergence of drug tolerance in PC9 cancer cell lines. In particular, we suggested that the
absence of non-genetic instability can result in the stabilization of the DTP phenotype in the surviving
population, so that DTEPs do not emerge, or even in extinction. This is a key result since it supports
the idea that epigenetic therapy may be a promising therapeutic strategy in the war against cancer [16–
18]. Another important prediction of our models is that the transient dominance of DTPs is strictly
related to the use of high doses of cytotoxic drugs. If experimentalists apply a lower dose of cytotoxic
agents to the PC9 cell population during drug therapy, we propose that it would be highly unlikely
to observe DTPs. Rather, we would expect the DTEPs to emerge directly from the PC9 population.
Note that this is the usual way to yield stable drug-tolerant lineages [19].
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Based on our models, we could conclude that if there are no DTPs present in the initial popula-
tion of PC9 cells, then it is likely that a proper interplay between non-genetic phenotype instability,
stress-induced adaptation and selection is mandatory for the transient appearance of the DTP pheno-
type during high-dose drug therapy. On the other hand, if there are some DTPs present in the initial
population, then non-genetic ﬂuctuations in phenotype and selection are enough to explain the ex-
perimental observations reported in [1]. Therefore, the next biologically meaningful question is: are
DTPs present in the initial population? Our analysis enabled us to propose a low cytotoxic drug-dose
experiment which could answer this question.
References
[1] S.V. Sharma, D.Y. Lee, B. Li, M.P. Quinlan, F. Takahashi, S. Maheswaran, U. McDermott,
N. Azizian, L. Zou, M.A. Fischbach et al., Cell 141, 69 (2010)
[2] C.A. Aktipis, A.M. Boddy, R.A. Gatenby, J.S. Brown, C.C. Maley, Nat Rev Cancer 13, 883
(2013)
[3] A. Kreso, C.A. O’Brien, P. van Galen, O.I. Gan, F. Notta, A.M. Brown, K. Ng, J. Ma, E. Wien-
holds, C. Dunant et al., Science 339, 543 (2013)
[4] A.O. Pisco, A. Brock, J. Zhou, A. Moor, M. Mojtahedi, D. Jackson, S. Huang, Nat Commun 4,
2467 (2013)
[5] K.P. Williams, J.L. Allensworth, S.M. Ingram, G.R. Smith, A.J. Aldrich, J.Z. Sexton, G.R. Devi,
Cancer Lett 337, 77 (2013)
[6] R.H. Chisholm, T. Lorenzi, A. Lorz, A.K. Larsen, L. Neves de Almeida, A. Escargueil,
J. Clairambault, Cancer research 75, 930 (2015)
[7] A.R. Anderson, A.M. Weaver, P.T. Cummings, V. Quaranta, Cell 127, 905 (2006)
[8] D.A. Charlebois, N. Abdennur, M. Kaern, Phys Rev Lett 107, 218101 (2011)
[9] A.S. Silva, R.A. Gatenby, Biol Direct 5, 25 (2010)
[10] M. Delitala, T. Lorenzi, J Theor Biol 297, 88 (2012)
[11] O. Lavi, J.M. Greene, D. Levy, M.M. Gottesman, Cancer Res 73, 7168 (2013)
[12] A. Lorz, T. Lorenzi, M.E. Hochberg, J. Clairambault, B. Perthame, ESAIM-Math Model Num
47, 377 (2013)
[13] R.J. Gillies, I. Robey, R.A. Gatenby, J Nucl Med 49, 24S (2008)
[14] K.S. Korolev, J.B. Xavier, J. Gore, Nat Rev Cancer Reviews Cancer 14, 371 (2014)
[15] C. Becker, J. Hagmann, J. Müller, D. Koenig, O. Stegle, K. Borgwardt, D. Weigel, Nature 480,
245 (2011)
[16] T. Clozel, S. Yang, R.L. Elstrom, W. Tam, P. Martin, M. Kormaksson, S. Banerjee, A. Vasan-
thakumar, B. Culjkovic, D.W. Scott et al., Cancer Discov 3, 1002 (2013)
[17] R.A. Juergens, J. Wrangle, F.P. Vendetti, S.C. Murphy, M. Zhao, B. Coleman, R. Sebree,
K. Rodgers, C.M. Hooker, N. Franco et al., Cancer Discov 1, 598 (2011)
[18] W. Timp, A.P. Feinberg, Nat Rev Cancer 13, 497 (2013)
[19] M.M. Gottesman, Annu Rev Med 53, 615 (2002)
ITM Web of Conferences
00009-p.4
